ArticleFrontiers in neuroscience2026
Modulating autonomic nervous system activity with transcutaneous auricular vagus nerve stimulation in Parkinson's disease: a proof of concept study.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular dysautonomia is a debilitating non-motor symptom of Parkinson's disease (PD) that limits exercise capacity and neurorehabilitation outcomes. Transcutaneous auricular vagus nerve stimulation (taVNS) is an emerging non-invasive neuromodulatory therapy that modulates cardiovascular activity and could potentially serve as an adjunct to exercise, yet its physiological effects on cardiovascular function in PD remains unexplored. Objective: This proof-of-concept, sham-controlled crossover pilot study ( Methods: Participants underwent active taVNS (30 Hz, 250 μs, 0.1-4 mA) or sham stimulation (0 mA) during a 15-min resting phase, immediately followed by the Ewing Battery of cardiovascular reflexes. Acute autonomic shifts were phenotyped using continuous heart rate variability (HRV) monitoring. Results: This proof-of-concept protocol was feasible, as all participants completed the randomized crossover stimulation visits and autonomic reflex testing without adverse events. Baseline autonomic burden (COMPASS-31) was associated with the magnitude of heart rate response to active stimulation. Immediately following stimulation and during the deep breathing challenge, active taVNS was associated with directionally consistent changes in vagally mediated HRV metrics including RMSSD, pNN50, and HF power, relative to sham. Conclusion: Continuous HRV monitoring and autonomic reflex testing appears feasible for characterizing acute autonomic responses to taVNS in PD. Active stimulation was associated with directional changes in vagally mediated HRV metrics during the post-stimulation period and during deep breathing, supporting the biological plausibility of acute autonomic modulation. These preliminary findings justify larger, adequately powered studies designed to determine whether taVNS can reliably modulate cardiovascular autonomic regulation and inform rehabilitation optimization in PD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.